EP1.03-30 FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC

Abstract

19/730) in non-small cell lung cancer, including Y856H (3 patients), M1689T (2 patients), N909I (2 patients), G275D (2 patients), N473S (2 patients), S1217C (1 patient), M1628T (1 patient), E649* (1 patient), R1443* (1 patient), V191I (1 patient), I783V (1 patient), M669T (1 patient), and R71K (1 patient), and median overall survival (OS) for these patients was 14.0 months. Among them, all patients were BRCA1 gene with co-occurring mutations. Briefly, patients with (n¼3) or without (n¼16) co-occurring EGFR mutations had a median OS of 20.0 months and 13.0 months respectively (P¼0.56); patients with (n¼4) or without (n¼15) co-occurring TP53 mutations had a median OS of 20.0 months and 19.5 months respectively (P¼0.82); patients with (n¼4) or without (n¼15) co-occurring PIK3CA mutations had a median OS of not up to now and 13.5 months respectively (P¼0.36); patients with (n¼5) or without (n¼14) co-occurring CDKN2A mutations had a median OS of not up to now months and 13.5 months respectively (P¼0.28). Conclusion: Our data reveal BRCA1 mutations represent a distinct subset of NSCLC. NGS might be useful for evaluation of BRCA1 unclassified variants. Our results show that BRCA1 mutations delineate an aggressive subtype of lung cancer for which a targeted treatment through PARP inhibition might offer new opportunities.